Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8932195 | 0.87 | MTNR1A (0.38) | MTNR1AMTNR1BSCN9AALDH1A1MAPT | |
| SCHEMBL584547 | 0.86 | SCN9A (0.49) | MTNR1AMTNR1BSCN9AALDH1A1MAPT | |
| SCHEMBL8932203 | 0.85 | SCN9A (0.35) | SCN9AALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL8932192 | 0.83 | CA1 (0.39) | MTNR1AMTNR1BALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL8932190 | 0.78 | EGFR (0.35) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13352198 | 0.77 | MTNR1A (0.46) | MTNR1AMTNR1BSCN9AMAPTTACR1 | |
| SCHEMBL584495 | 0.76 | SCN9A (0.47) | MTNR1AMTNR1BSCN9A | |
| SCHEMBL1571749 | 0.72 | SCN9A (0.47) | SCN9AALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL15962599 | 0.72 | SCN9A (0.51) | SCN9AALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL28858611 | 0.70 | CYP1A2 (0.34) | SCN9AALDH1A1MAPTCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5393908-A | Storage stable intermediate | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1995-02-28 | — | — | US | claimed |
| WO-1994000460-A9 | SYNTHESIS OF N-FORMYL-3,4-DI-t-BUTOXYCARBONYLOXY-6-(TRIMETHYLSTANNYL)-L-PHENYLALANINE ETHYL ESTER AND ITS REGIOSELECTIVE RADIOFLUORODESTANNYLATION TO 6-[18F]FLUORO-L-DOPA | — | 1994-02-17 | — | — | WO | claimed |
| WO-1994000460-A1 | SYNTHESIS OF N-FORMYL-3,4-DI-t-BUTOXYCARBONYLOXY-6-(TRIMETHYLSTANNYL)-L-PHENYLALANINE ETHYL ESTER AND ITS REGIOSELECTIVE RADIOFLUORODESTANNYLATION TO 6-[18F]FLUORO-L-DOPA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-01-06 | — | — | WO | claimed |
| US-7115249-B2 | Solid-phase electrophilic fluorination | GE HEALTHCARE LTD. (GB) | 2006-10-03 | — | — | US | disclosed |
| EP-1399401-B1 | SOLID-PHASE ELECTROPHILIC FLUORINATION | GE HEALTHCARE LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-20040186312-A1 | Solid-phase electrophilic fluorination | GE HEALTHCARE LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
| EP-1399401-A2 | SOLID-PHASE ELECTROPHILIC FLUORINATION | Amersham plc (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002489-A2 | SOLID-PHASE ELECTROPHILIC FLUORINATION | AMERSHAM PLC (GB) | 2003-01-09 | — | — | WO | disclosed |
| US-5510522-A | AMIDATION, IODINATION, METALLIZATION, RADIOFLUORINATION OF DOPA AND DERIVATIVES THEREOF; SHELF STABLE PRECURSOR, HIGH YIELDS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-04-23 | — | — | US | disclosed |
| US-5393908-A | Storage stable intermediate | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1995-02-28 | — | — | US | disclosed |
| WO-1994000460-A9 | SYNTHESIS OF N-FORMYL-3,4-DI-t-BUTOXYCARBONYLOXY-6-(TRIMETHYLSTANNYL)-L-PHENYLALANINE ETHYL ESTER AND ITS REGIOSELECTIVE RADIOFLUORODESTANNYLATION TO 6-[18F]FLUORO-L-DOPA | — | 1994-02-17 | — | — | WO | disclosed |
| WO-1994000460-A1 | SYNTHESIS OF N-FORMYL-3,4-DI-t-BUTOXYCARBONYLOXY-6-(TRIMETHYLSTANNYL)-L-PHENYLALANINE ETHYL ESTER AND ITS REGIOSELECTIVE RADIOFLUORODESTANNYLATION TO 6-[18F]FLUORO-L-DOPA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186312-A1 | Solid-phase electrophilic fluorination | CYP2F1, GSTP1, GSTA1 | MTNR1A 778/4885MTNR1B 975/4885SCN9A 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.